TCR2 Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$269.5M
Industry:Biotech
Founded:2015
Lead Investor(s):6 Dimensions Capital
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.
  • TCR2 Therapeutics received $125.0M in venture funding in March 2018.
  • TCR2 Therapeutics's estimated revenue per employee is $42,009
  • TCR2 Therapeutics's total funding is $269.5M.

Employee Data

  • TCR2 Therapeutics has 107 Employees.
  • TCR2 Therapeutics grew their employee count by 47% last year.
  • TCR2 Therapeutics currently has 14 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$7.1M5660%N/A
Tango Therapeut...
$9M8338%N/A
Compass Therape...
$15.8M10614%N/A
Cell Signaling ...
$75.6M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$14.7M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$14.6M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.

keywords:Biotechnology,Healthcare

107

Number of Employees

$4.5M

Revenue (est)

14

Current Jobs

47%

Employee Growth %

$269.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Amy LynchHead Of Operations And Human Resources
Robert HofmeisterChief Scientific OfficerEmail Available
Robert TigheVp, Translational ResearchEmail Available
Seth ClarkeCMC Project ManagerEmail Available
Peter SmithSr. Accounting ManagerEmail Available
Andrew CornforthVice-president Of Process DevelopmentEmail Available
Prakash PrabhakarSr. Director, Program Management & Clinical Operations
Reshma SinghDirector
Kenanova VaniaAssociate Director
Ian HardyPrincipal ScientistEmail Available

TCR2 Therapeutics News

12-Sep-19 - TCR2 Therapeutics, NCI Team Up to Test TC-210 ...

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...

31-Aug-19 - TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?

TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...

24-Aug-19 - How Much Of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Do Institutions Own?

If you want to know who really controls TCR2 Therapeutics Inc. (NASDAQ:TCRR), then you'll have to look at the makeup of its share registry.

TCR2 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-12-12$44.5MAMPM CapitalArticle
2018-03-22$125.0MB6 Dimensions CapitalArticle

TCR2 Therapeutics Executive Hires

DateNameTitleReference
2017-10-12Alfonso CardamaChief Medical OfficerArticle
2018-04-11Ian SomaiyaCFOArticle